Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373: <i>in vitro</i> analysis and clinical validation
Sarah P. Blagden(Churchill Hospital), David J. Harrison(NHS Lothian), Jordan Berlin(Dana-Farber Cancer Institute), Kristen K. Ciombor(The Ohio State University), Fiona G. McKissock(Nucana (United Kingdom)), Michelle Myers(Nucana (United Kingdom)), Janet S. Graham(Beatson West of Scotland Cancer Centre), Francesca Aroldi(Churchill Hospital), Lisa Rodgers(Beatson West of Scotland Cancer Centre), T.R. Jeffry Evans(Leiden University Medical Center)
Cited by 1
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
High-frequency developmental abnormalities in p53-deficient mice
|Current Biology|1995|467